Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Clinical Study of First-line Treatment of Small Cell Lung Cancer (SCLC) With Anlotinib Hydrochloride in in Combination With EC/EP

NCT03890055 is registered in ClinicalTrials.gov with Chifeng Municipal Hospital as lead sponsor.

NCT NCT03890055
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03890055 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Clinical Study of First-line Treatment of Small Cell Lung Cancer (SCLC) With Anlotinib Hydrochloride in in Combination With EC/EP
Lead sponsor
Chifeng Municipal Hospital
Phase
Phase 4
Overall status
Unknown status
Start date
April 1, 2019
Completion date
October 1, 2020
Enrollment
30 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

small cell lung cancer